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ABSTRACT 
Co-trimoxazole appropriates to category of broad-spectrum antimicrobial. They are active upon administration in vitro against an extensive 
collection of microorganisms. Their application in medical field has roughly spanned over decade now. There are numerous approaches that were 
progressed for improving their effectiveness towards their antimicrobial potency. However, routine use of this could accelerate the chance of 
bacterial resistance, and portrait it ineffective when required to treat infection. Consequently, newer investigations are necessary to keep the drug 
effective by minimise the development of resistance and maximise its safe use. Safe use is meant by safe delivery of drug in low dose, low frequency 
at the targeted molecule by effective ways. This can be achieved by using nanocarrier systems as they possess smart characteristics of effective drug 
delivery. These nanocarrier systems are including nanoparticle, liposomes, nanogels etc. Present review article deals with the historical 
perspectives with regards to co-trimoxazole, their mechanism of act/resistance and spectrum of activity in first section. In second portion different 
novel carriers, importance and application of nanogels, rational for co-trimoxazole nanogels are discussed. In conclusion, different literatures have 
proved the efficacy of nanogels in delivery of antimicrobial drug similar to co-trimoxazole. In the present time very less data is available for delivery 
of this drug with novel carriers. Therefore, this review aims to encourage researchers for creating some new findings in this perspective. 
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INTRODUCTION 
Phenomenon pertaining to multidrug-resistant (MDR) is presenting an 
intensifying tendency and signifies key challenge for a system of health 
care [1]. The situation is particularly more drastic for “ESKAPE” 
pathogens containing Enterococcus spp., Klebsiella spp., Staphylococcus 
aureus, Pseudomonas aeruginosa, Acinetobacter baumannii and 
Enterobacter spp. A few of these pathogens like Acinetobacter. 
baumannii, already become pan-resistant [2]. Co-trimoxazole (CTX) is 
a combination of sulpahamethoxazole and trimethoprim (SMX/TMP) 
in the proportion of 5:1. The combination is having potential 
synergistic effect. Both the drugs have equal t1/2
CTX is primarily available in tablet (TMP 80/160 mg and SMX 400 
mg) and suspension (TMP 40 mg/5 ml and SMX 200 mg/5 ml) form. 
However, for treatment in advance cases parenteral preparations 
like injection concentrate for IV infusion (TMP 16 mg/ml and SMX 
80 mg/ml) is also available. Fig. 1 depicts its different functional 
attributes. 
 of approximately 10 
h, making them suitable for this combination. They block the 
sequential obligate enzymatic reaction in bacteria. Sulfamethoxazole is 
a close congener of sulfisoxazole. The same combination is also 
popularly known as Bactrim, Septran and proven as clinically 
successful antimicrobials. It is originated as the agent of first choice 
only in Pneumocystis carinii infections; however, it is essential in 
several infectious diseases like UTI, throat, ear infections, enteric fever 
and acute exacerbations of chronic bronchitis [3].  
From the historical perspective, CTX belongs to the family of the 
renowned sulphur family of sulphanilamides, which are derivatives 
sulphanilamide, which is chemically known as para-amino benzene 
sulfonamide. Major groups of sulfonamides are relatively water 
insoluble, but their sodium, potassium salts is water-soluble. The 
antibacterial action of these compounds is inherited due to sulfanilamide 
structure itself, which portrays the sulphur linked directly to the 
benzene ring having a substitution in the amide NH2 
Sulfonamides competitively block bacterial enzyme dihydropteroate 
synthase, responsible for the conversion of para-aminobenzoic acid 
into folic acid. TMP shows a synergistic action with all sulfonamides 
by selectively blocking bacterial dihydrofolate reductase. This 
enzyme is responsible for reducing dihydrofolate to 
tetrahydrofolate. The potential combination of these two drugs for 
the broad-spectrum action is 20:1 of SMX and TMP. Generally, all the 
sulfonamides get well absorbed when administered orally with peak 
plasma levels around 2–6 h. They have good volume of distribution 
(50–80%). They easily reach the cerebrospinal fluid [5, 6)].  
group [4]. 
In past few years the uses of CTX accelerate the chance of bacterial 
resistance, and results in treatment failure. Therefore, there is a 
continuous demand of new therapeutic agents and delivery system 
which can keep the drug effective by minimise the development of 
resistance and maximise its safe use. Most of the research focussed 
on development of novel delivery system/nanocarrier like 
nanoparticle, liposomes, nanogels which possess smart 
characteristics of effective drug delivery. The present review 
highlights the importance and applications of nanogel and recent 
updates on the CTX loaded nanocarriers systems.  
Authors conducted a systematic review of published literature to 
assess the current use and advancement of CTX and its nanocarrier 
system in the treatment of bacterial disease. In the present time very 
less data is available for the delivery of CTX with nanocarriers. 
Therefore, this review aims to encourage researchers for creating 
some new findings in this perspective. 
A search of the computerized bibliographic database; PubMed, Google, 
Scopus and Google Scholar was performed. The keywords used in the 
search were co-trimoxazole, drug resistance, antimicrobials, 
nanocarriers and co-trimoxazole based nanocarriers. Original articles, 
review articles and expert’s opinions published between 2009 to 2020 
that investigated or discussed the nanocarrier system and novel delivery 
systems of CTX were used in this article. 
Co-tr imoxazole: pharmacological character istics and mechanism 
of action 
It is a combination of synergistic of 2 antimicrobial agents, namely: 
SMX and TMP. The mechanism of action is its interference against 
synthesis of folic acid synthesis of bacterial species. Mechanism 
underlying CTX tend to impact bacteria which are capable to take 
folic acid from infected hosts; thereby, they are dependent on its 
self-synthesis of folic acid (fig. 2).  
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Both TMP as well as the SMX exhibit better result upon combination 
compared to when they are administered separately since it inhibits 
successive steps that folate synthesis way. It is done by challenging 
with p-aminobenzoic acid (PABA) in the biosynthesis of 
dihydrofolate. TMP helps as a competitive inhibitor of dihydrofolate 
reductase [7-8].  
Tetrahydrofolate is the synthesis of purines, which is vital, 
thymidine, and methionine, which are in necessity for DNA 
production and proteins through replication of bacteria. The 
consequence of both of these drugs is a stayed in bacteriostatic 
replication. If both are combined, SMX and TMP are bactericidal. 
Over enzymatic inhibition starves bacteria in 2 bases, which are 
(thymidine and uridine) as it is important for replication along with 
transcriptions of DNA. This particular mechanism of action resulted 
in their application mainly for treating urinary tract contaminations, 
prophylaxis and in treating Pneumocystis jiroveci pneumonia for 
human immune virus-contaminated patients [9-11]. Alsaad et al. 
observed the pharmacokinetic parameters for tuberculosis patients. 
Using CTX with regards to clearance, area under curve, the volume 
of delivery alongside with other indications also. From the analysis, 
it could be determined that it was safe and also well-tolerated; 




Fig. 1: Functional attributes of Co-trimoxazole [6] 
 
 
Fig. 2: Mechanism exhibited by Co-trimoxazole against microorganisms [6] 
 
Under the general note, CTX serves to be a safe medication and the 
drug is tolerated well. However, certain possible side-effects that are 
witnessed with the administration of drugs such as: gastrointestinal 
intolerance, vomiting, nausea, diarrhoea and anorexia [13]. Thus, the 
probable side effects are observed in the blood, such as 
hypokalaemia, also with a small upsurge on serum creatinine levels 
observed and hypernatremia. Such effects tend to occur 
predominantly amongst patients suffering renal dysfunction. Also, 
the haematological abnormalities observed comprise leukopenia, 
thrombocytopenia, agranulocytosis and aplastic and haemolytic 
anaemia [14]. Research investigations emphasizing on the in vitro 
activities of CTX pertaining to the antibacterial action were studied 
by researchers for many years. The table 1 portrays on various 
literature sources, stressing on in vitro antibacterial activity of CTX. 
  
Table 1: Literature sources on in vitro antibacterial studies 
In vitro studies carried out by Targeted bacterial species Outcomes 
Lewin et al. [15] Pseudomonas cepacia The MICs in case of ceftazidime, meropenem, ciprofloxacin and PD over 90% 
tested strains were lesser or equivalent to 4 micrograms/ml, whereas they 
were 32 µg/ml in the case for chloramphenicol/co-trimoxazole. 
Betriu et al. [16] Stenotrophomonas maltophilia Isolates of the study showed that resistance towards CTX has decreased  
Hahn and Kirov [17] Klebsiella pneumoniae, Proteus 
mirabilis, Proteus vulgaris, and 
Streptococcus faecalis. 
It showed optimal antibacterial potency with a weight ratio ranging for 
benzyl pyrimidine/sulfonamide with equivalent 1:1 otherwise 1:5, 
respectively. Under all instances, combinatorial indications suggest 
trimethoprim/sulfamethoxazole as higher antibacterial from in vitro study 
than tetroxoprim/sulfadiazine. 
Minkowski et al. [18] 
 
Listeria monocytogenes At maximal concentration ranges of co-trimoxazole/TMP exhibited matrix 
(cell lysis), disruption observed in membrane, and bacterial fragmentation  
Forgacs et al. [19] Mycobacterium tuberculosis 43 out of 44 isolates of   M. tuberculosis were sensitive to ≤1/19 μg/ml of 
TMP-SMX. 
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Nano-antimicrobials: next course of action against pathogenic 
microbes 
For the escalating resistance to mostly all classes of antibiotics is 
decreasing utilities of presently accessible antimicrobial drugs [20]. 
A portion of the threat is recognized to deprive pharmacokinetics 
and pharmacodynamics drug. Development of drug delivery is likely 
the maximum exciting task that comes across by pharmaceutical 
industries, though nanotechnology that can take along a rebellion in 
plan and drug delivery. Nano-antimicrobials, they consume action of 
separate intrinsic antimicrobial or augment complete efficiency of 
antibiotics surrounded, thus the contribution in mitigation or 
retrieving resistance phenomenon [21]. 
Individual intrinsic antimicrobial activity having by nanoparticle, 
that destroys the microbes by imitating killing course through 
phagocytic cells, by creating an enormous amount of responsive 
species of oxygen and responsive nitrogen species. Nanoparticles are 
killing microbes by concurrently substitute on numerous vital life 
procedures or metabolic ways of microbes [22]. Nano-carriers 
increase pharmacokinetics of drugs enclosed. Likewise, the crucial 
methods by which nanomaterials could overwhelm resistance is 
drug delivery target of disease. Nano anti-microbials exhibits 
various mechanisms (fig. 3) by which they combat the multidrug-
resistance phenomenon [23]. 
The nanocarrier (vesicular and particulate) like liposomes, transfer 
some, niosomes, solid lipid nanoparticles, microspheres, micelles, 
dendrimers etc. are broadly used nowadays for their antimicrobial 
property in nanomaterial. A list of important nanocarriers used for 
delivering antimicrobials has been depicted in table 2. 
 
 
Fig. 3: Nano anti-microbials and their different mode of actions, (1-Attachment to 30s ribosome subunits; 2-Damage/disruption of proton 
pumps; 3-Protein damage; 4-Prevention of Biofilm formation; 5-DNA damage; 6-Disruption of electron transport chain; 7-Disruption of 
microbial cell membrane; 8* Generation of ROS) [23] 
 
Nanoparticles 
Antimicrobial nanoparticles now in use are metal, metal oxide, and 
organic nanoparticles type. They show a diversity of intrinsic and 
modified chemical composition properties. Silver and gold metal 
nanoparticles are established for their antimicrobial efficacy. 
Polymeric nanoparticles destroy microorganisms either by releasing 
the entrapped antimicrobial agents or by direct contacting with 
cationic surfaces such as quaternary ammonium compounds to the 
negatively charged bacterial cell [24]. 
Liposomes 
These are defined as microscopic (unilamellar or multilamellar 
vesicles) and are composed of phospholipids, cholesterol and long 
chain fatty acids. The advantages of liposomes include non-toxic, 
biocompatible, non-immunogenic, biodegradable and able to protect 
the encapsulated material. Liposomes have been employed to 
deliver many antimicrobials to the lungs. They provide an excellent 
control release of drug in the lungs and is stable. Many liposomal 
preparations of antimicrobials like Arikace® (liposomal amikacin) 
and Pulmaquin® (liposomal ciprofloxacin) have reached to advance 
phases of the clinical trials [25, 26]. 
Niosomes 
These are non–ionic surfactant-based liposomes i.e. microscopic 
lamellar structures obtained on the hydration of non-ionic surfactant, 
cholesterol and other lipids. These are cheaper to prepare than 
liposomes and are highly resistant to oxidation. It comprises both 
hydrophobic and hydrophilic moiety and these were developed for 
reducing systemic toxicity by encapsulating the drug and minimize the 
clearance of its release slowly in the body. In a study, cephalexin-
loaded niosomal formulations were made using span 60 and tween 60. 
The developed formulation exhibits an enhanced in antibiotic activity 
against E. coli and S. aureus as compared to free drug. Moreover, the 
niosomal formulation was stable and exhibited slight cytotoxicity in 
HepG2 cells, measured by MTT assay [27]. 
Polymeric microspheres 
These are made of solid polymeric spherical particles (1-1000 µm) 
in which the drug is distributed through the matrix containing 
polymer. These are effective for delivering therapeutic substances to 
the target site in a sustained and controlled manner. The main 
advantages of this system are to protect the unchangeable drug 
before and after administration and thus improve the bioavailability, 
reduces the incidence or intensity of adverse effects, provide 
extended therapeutic effects and improve patient compliance. In a 
study, Thaya et al. developed a chitosan-alginate microsphere with 
high antifilm and antimicrobial activity against bacteria of public 
health relevance [28]. Similarly, Adebisi et al. also formulated 
clarithromycin-loaded ethylcellulose/chitosan microspheres for 
treatment of H. pylori for the treatment of peptic ulcer [29]. 
Hydrogels 
These are a hydrophilic network of polymers, mainly of 3d structure, 
according to their ionic interaction and hydrogen bonding. The 
advantages include biocompatibility and their ability to bring 
changes of pH, temperature and other stimulation factors that can be 
easily injected and can absorb water, easily modify. Currently, 
hydrogels loaded with antimicrobial agents are a hotspot for 
research in the biomedical field. In the recent past, many advance 
hydrogels loaded with antibacterial have been developed, 
possessing qualities like high swellability, ease of drug loading and 
controlled drug release with a vast structural diversity [30]. 
Dendrimers 
They are characterized as a 3D macromolecular structure with 
various branching units and multiple active terminal groups. The 
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drug can be administered both in the interior region, including the 
surface groups of the dendrimers. These provide miscellaneous 
advantages such as less susceptibility to uptake by the 
reticuloendothelial system, comfort of modification, targeting to a 
specific location in the body make sure generative, pharmacokinetic 
behavior [31]. 
Solid lipid nanoparticles 
It contains a solid lipid core matrix that is used to solubilize 
lipophilic molecules. A greater quantity of surfactants is used to 
stabilize the lipid core. They are typically spherical and their size 
ranges from 10 to 1000 nm. Li C et al. developed a solid lipid 
nanoparticle (SLN) of enrofloxacin by a hot homogenization and 
ultrasonic emulsification method. The developed SLN exhibits good 
stability with an increased in area under the curve and mean 
retention time as compared to the pure drug. The SLN improved oral 
bioavailability, palatability, sustained-release performance and 
stability of enrofloxacin [32]. Jansook et al. formulated Amphotericin 
B-loaded SLN and studied the drug release profile, entrapment 
efficiency and biopharmaceutics of amphotericin B. They reported 
that the Amphotericin B-loaded SLN exhibit increased antifungal 
activity with a prolong release characteristic [33]. In a study, 
Chokshi et al. developed rifampicin-loaded SLN by employing a 
three-level, three-factor Box-Behnken design for the treatment of 
tuberculosis. The developed SLN exhibited the antilipolytic effect 
and in vitro gastrointestinal tract (GIT) stability studies (at pH 1.2, 
pH 4.5, pH 6.8, and pH 7.4) shows that the SLN can withstand 
various GIT media [34]. 
Micelles 
Micelles are spherical amphiphilic structures that have a 
hydrophobic core and a hydrophilic shell. The main merits of these 
micelles are the biocompatibility, similar biological activity, 
sustained release of encapsulated materials, competence to act as 
long-circulating drug carriers, the elevated solubility of hydrophobic 
drugs and ability of therapeutic proteins to the target site. The above 
merits lead to the development of drug-loaded micelles in the 
delivery of antimicrobial agents. In a recent study, Zhou et al. 
developed tobramycin-embedded nanostructured pH-responsive 
micelles with efficient and sustained antibacterial properties [35]. 
Nanoemulsion 
These are nano-sized emulsions. The main advantage of 
nanoemulsion is the loading of less amount of the drug so that it will 
show fewer side effects with a high dose of the drug and also help in 
the delivery of the poorly soluble drug into the bottom of the skin 
layer. The absorption rate increases when the drug particle size 
ranges from 10-200 nm. The main advantage is to provide the 
controlled release, sustained release of the drug to the target site 
and is easily reproducible [36]. 
 
Table 2: List of reported literature for nanocarrier of antibacterial drugs 
Nanocarrier  Drug Targeted pathogen References 
Liposomes Azithromycin MAC, Pseudomonas. aeruginosa [37] 
Gentamicin Listeria monocytogenes, Salmonella spp., Brucella abortus, Pseudomonas aeruginosa  [38, 39] 
Ampicillin Helicobacter pylori, Serovar Typhimurium, Salmonella enterica [40, 41] 
Ciprofloxacin Streptococcus aureus, Francisella tularensis, Pseudomonas aeruginosa [42-45] 
Polymer 
nanoparticles 
Vancomycin Enterococcus clinical isolates, Streptococcus aureus [46] 
Ampicillin  Pseudomonas aeruginosa, Streptococcus aureus, Enterobacter aerogenes, [47] 
Penicillin  MRSA [48] 
Azithromycin Haemophilus influenzae, Escherichia coli, Streptococcus pneumoniae, Chlamydia pneumoniae, [49-50] 
Isoniazid  Mycobacterium spp. [51] 
Rifampicin Mycobacterium bovis, Chlamydia pneumoniae, Chlamydia trachomatis [52] 
Solid lipid 
nanoparticles 
Amikacin  Pulmonary infections and Pseudomonas aeruginosa [53] 
Gatifloxacin Streptococcus aureus (MRSA) [54] 
Norfloxacin Escherichia coli [55] 
Dendrimers Rifampicin.  Mycobacterium spp [56] 
Vancomycin Streptococcus aureus [57] 
Amoxicillin  Escherichia coli, Streptococcus aureus [58] 
MRSA: methicillin-resistant Streptococcus aureus; MAC: Mycobacterium avium 
 
Cotrimoxazole loaded novel drug delivery systems 
Usually, antimicrobial agents are administered by oral or parenteral 
route in the form of capsules/tablets and injections, 
correspondingly. Topical antimicrobial preparations like ointments, 
gels and creams are also employed for local or systemic function. 
Unfortunately, this systemic antimicrobial drug delivery is 
associated with numerous challenges. The common problem is body 
tissues getting exposed to high concentrations of potent drugs when 
administered orally or parenterally relatively than that required at 
the site of action. It means the delivery is non-specific and thus 
creates a large number of unwanted side effects and sometime 
potential toxicity (in case of anticancer). Other limitations are 
1. It requires larger doses due to first-pass metabolism or 
enzymatic destruction  
2. Antimicrobials destroy friendly bacteria naturally present in the 
gut and therefore create unwanted problems, including fatalities.  
3. In some conditions like venous ulcers or infected diabetic foot, 
systemic administration is unsuccessful due to low blood circulation 
in the extremities, particularly in diabetics.  
4. Unnecessary large dose through systemic administration is not 
rational in local infections where low local doses may be beneficial. 
For these reasons, novel delivery systems of these antimicrobials 
have been explored to overcome the above-mentioned limitations of 
conventional antimicrobial delivery. Many of these novel delivery 
systems modify the conventional (oral and parenteral) drug delivery 
by controlled or sustained delivery systems. Therefore, allow long-
lasting maintenance of therapeutic doses in the systemic circulation 
and evade from repeated doses. Some of this novel delivery 
approaches are discussed in this section. 
In a study, Kumar et al., prepared a hydrogel loaded with CTX for the 
wound healing activity. The formulation can simultaneously deliver 
TMP/SMX at the wound site and accelerated the healing process. 
They prepared chitosan loaded CTX nanoparticle by an ion gelation 
method with a size range of 209.8 nm. The hydrogels were prepared 
on the basis of the concentration of carbopol 940. The hydrogel 
exhibits a MIC of µg/ml and zone of inhibition 3.7±0.3 times more 
than the plain drug after 72 h. The hydrogel releases the CTX in a 
sustained release fashion. The in vivo study showed that the 
hydrogel can heal the wound 1.5 times faster than the conventional 
marketed formulation [59]. Similarly, Attama AA et al. prepared a 
CTX loaded mucoadhesive microparticle through emulsification 
method employing mucin and carbopol 941. They observed that the 
complexation of mucin with carbopol modified the physical property 
of carbopol. The microparticle exhibits good mucoadhesion property 
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with drug entrapment and fluid sorption. They concluded that the 
optimized mucoadhesive microparticles having mucin and carbopol 
941 in the ratio 1:1 shows a sustained release of CTX [60]. Amaral 
AC et al. tested the activity of peptide P10 (an immunomodulator) 
through a sustained delivery system in combination with TMP/SMX 
against paracoccidioidomycosis. In an animal model, the chronic 
form of paracoccidioidomycosis was induced in BALB/c mice with 
Paracoccidioides brasiliensis. The mice were treated with TMP/SMX 
alone or combination with peptide P10, either emulsified in Freund's 
adjuvant or loaded with poly (lactic acid-glycolic acid) (PLGA) 
nanoparticles. Quantitative level of cytokines and fungal burden in 
tissues was measured to assess the therapeutic efficacy of the 
treatments. The mice treated with PLGA nanoparticles presented a 
remarkable reduction in the fungal load in lungs as compared to the 
non-treated animals. Moreover, the PLGA nanoparticle was found to 
be more effective as compared to the emulsion form. Thus, they 
concluded that the PLGA nanoparticle loaded with TMP/SMX and 
P10 peptide demonstrated an increase activity against the fungus 
and reduce the degradation of P10 peptide [61]. In another study 
Bottari NB et al. investigate the synergistic effects of TMP/SMX and 
resveratrol inclusion complex nanoparticle on Toxoplasma gondii 
infected of mice. They divided 60 mice into 2 groups: uninfected (n = 
24) and infected by T. gondii (n = 36) which was further subdivided 
into treated with resveratrol or TMP/SMX alone and co-
administered with of TMP/SMX and resveratrol inclusion complex 
nanoparticle. They studied the behavioral test and various 
pathological changes including brain cyst count. They reported that 
the nanoparticle treated mice showed a reduced cyst in the brain 
and diminished lesion in the liver. The nanoparticle also increased 
the antioxidant level in the mice and prevent behavioral changes. 
Therefore, they concluded that the TMP/SMX and resveratrol 
inclusion complex nanoparticle shows an improved therapeutic 
effect with reduced oxidative stress, which results in liver protection 
and reduced cysts in the brain of T. gondii infected mice [62]. 
Mendes C et al. developed a supersaturating delivery system by solid 
dispersion technique containing TMP/SMX at fixed-dose 
combination (SMX: TMP 5:1 w/w). They proposed that the retention 
of supersaturation drugs in the intestinal lumen can result in higher 
bioavailability. The drug was made amorphous by spray drying and 
then solid dispersion was formulated with the help of Eudragit EPO 
polymer. The formulation containing 70% of Eudragit EPO 
maintains the supersaturation condition up to 24 h. Moreover, the 
formulation showed an improved antibacterial activity as compared 
to pure drugs alone. Thus, the developed formulation improves the 
bioavailability of drugs with reduce the dose and may be helpful in 
the prevention of antibiotic resistance emergence [63]. The SMX in 
CTX is a is insoluble in water, resulting in low bioavailability and 
limits its clinical use. Gurbuz MU et al. synthesis a surface-modified 
polyamidoamine (PAMAM) dendrimers loaded with SMX for 
enhancing the solubility. The results stated that the dendrimers 
increase the solubility of the SMX. Among various formulations, the 
NH2
CONCLUSION 
 group containing PAMAM dendrimers exhibits highest aqueous 
solubility. In addition, in an in vitro drug release studies, the 
dendrimers exhibit a sustained release of SMX as compared to pure 
drug at the end of 2 h [64]. Similarly, Gokturk S, et al. also enhances 
the solubility of TMP/SMX by inclusion it in cyclodextrins (α-, β-, and 
γ-CDs) and anionic surfactant sodium dodecyl sulfate (SDS) [65]. 
Bodaghabadi et al., formulated CTX and rifampicin loaded 
nanoparticles. Studies showed CTX efficiency didn’t improve by 
stuffing into nanoparticles, the CTX ineffectiveness is expected not 
because of its insolubility or low penetration, and perhaps there are 
some other issues that persist to be making clear for the future 
investigations [66].  
The review signifies that currently, numerous forms of nanocarrier 
based compounds tailored to meet up with various needs 
applications. The promising attributes for hydrogels primarily are as 
an outcome of its swelling under the contact of the aqueous 
environment. The review demonstrated literature pertaining to 
hydrogel classification on the basis of dissimilar bases, physic-
chemical features of products along with technical likelihood over 
utilization. CTX is one of the potent antibiotics with a wide array of 
applications for treatment against numerous bacterial species for 
nearly two decades. However, there still appears that there exists no 
proper investigation pertaining to nanocarrier loaded CTX or in 
combination. It is quintessential to researchers in coming future 
towards synthesis of novel and efficacious CTX loaded nanocarriers 
to minimize its resistance problem and exploit its safe use. 
ACKNOWLEDGEMENT 
RD, RKH and MS would like to thank the Institute of Pharmaceutical 
Research, GLA University, Mathura for providing necessary facilities 
and support. SDP would like to thank Dr. A. K. Jha, Principal, FPS-




All the authors have contributed equally. 
CONFLICT OF INTERESTS 
No conflict of interest. 
REFERENCES 
1. Kulkarni A, Deo A, Nimbarte S. Antibiotic resilience pattern and 
cetrimide induced ultrastructural changes in multidrug 
resistant S. aureus. JCR 2020;7:1053-65. 
2. Tacconelli E, Carrara E, Savoldi A. Discovery, research, and 
development of new antibiotics: the WHO priority list of 
antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 
2018;18:318-27. 
3. Suryana K, Suharsono H, Sindhughosa DA. Co-trimoxazole 
preventive therapy reduces active pulmonary tuberculosis risk 
in people living with HIV/AIDS on antiretroviral at wangaya 
hospital in Benpasar, Bali, Indonesia: a prospective cohort 
study. Asian J Pharm Clin Res 2020;13:96-100.  
4. Patel RB, Welling PG. Clinical pharmacokinetics of co-
trimoxazole (trimethoprim-sulphamethoxazole). Clin 
Pharmacokinet 1980;5:405-23. 
5. Masters PA, O’Bryan TA, Zurlo J, Miller DQ, Joshi N. 
Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 
2003;163:402–10. 
6. Church JA, Fitzgerald F, Walker AS, Gibb DM. The expanding 
role of co-trimoxazole in developing countries. Lancet Infect 
Dis 2015;15:327-39. 
7. Hawser S, Lociuro S, Islam K. Dihydrofolate reductase 
inhibitors as antibacterial agents. Biochem Pharmacol 
2006;71:941-8. 
8. Swarbrick J, Iliades P, Simpson JS, Macreadie I. Folate 
biosynthesis–reappraisal of old and novel targets in the search 
for new antimicrobials. Open Enzyme Inhibition J 2008;1:12-33. 
9. Bermingham A, Derrick JP. The folic acid biosynthesis pathway 
in bacteria: evaluation of the potential for antibacterial drug 
discovery. Bioessays 2002;24:637-48. 
10. Sharma N, Aron N, Agarwal T, Sharma C. Pharmacology of ocular 
therapeutics. In: Velpandian T. editors. Antimicrobial agents for 
ocular use: bacterial, fungal, viral, and protozoal infections. 1st ed. 
Switzerland: Springer International Publisher; 2016. p. 285-32.  
11. Helweg Larsen J, Benfield TL, Eugen Olsen J, Lundgren JD, 
Lundgren B. Effects of mutations in pneumocystis carinii 
dihydropteroate synthase gene on outcome of AIDS-associated 
P. carinii pneumonia. Lancet 1999;354:1347-51. 
12. Alsaad N, Van Altena R, Pranger AD. Evaluation of co-
trimoxazole in the treatment of multidrug-resistant 
tuberculosis. Eur Respir J 2013;42:504-12. 
13. Lacey RW, Hawkey PM, Devaraj SK, Millar MR, Inglis TJ, Godwin 
PG. Co-trimoxazole toxicity. Br Med J (Clin Res Ed) 1985;291:481.  
14. Alsaad N, Wilffert B, Van Altena R, De Lange WC, Van der Werf 
TS, Kosterink JG, et al. Potential antimicrobial agents for the 
treatment of multidrug-resistant tuberculosis. Eur Respir 
J 2014;43:884-97. 
15. Lewin C, Doherty C, Govan. In vitro activities of meropenem, PD 
127391, PD 131628, ceftazidime, chloramphenicol, co-
trimoxazole, and ciprofloxacin against Pseudomonas 
cepacia. Antimicrob Agents Chemother 1993;37:123-5. 
Deshmukh et al. 
Int J App Pharm, Vol 13, Issue 1, 2021, 36-42 
41 
16. Betriu C, Sanchez A, Palau ML, Gomez M, Picazo JJ. Antibiotic 
resistance surveillance of Stenotrophomonasmaltophilia, 
1993–1999. Antimicrob Agents Chemother 2001;48:152-4. 
17. Hahn H, Kirov A. Antibacterial activity of co-trimoxazole and 
tetroxoprim/sulfadiazine in vitro. Arzneimittel Forschung 
1980;30:1047-8. 
18. Minkowski P, Staege H, Groscurth P, Schaffner A. Effects of 
trimethoprim and co-trimoxazole on the morphology of Listeria 
monocytogenes in culture medium and after phagocytosis. 
Antimicrob Agents Chemother 2001;48:185–93. 
19. Forgacs P, Wengenack NL, Hall L, Zimmerman SK, Silverman 
ML, Roberts GD. Tuberculosis and trimethoprim-
sulfamethoxazole. J Antimicrob Chemother 2009;53:4789-93. 
20. Jamil B, Bokhari H, Imran M. Mechanism of action: how nano-
antimicrobials. Act. Curr Drug Targets 2017;18:363-73. 
21. Beyth N, Houri Haddad Y, Domb A, Khan W, Hazan R. 
Alternative antimicrobial approach: nano-antimicrobial 
materials. J Evidence Based Complementary Altern 
Med 2015;2015:246012. 
22. Park K. Facing the truth about nanotechnology in drug 
delivery. ACS Nano 2013;7:7442-7. 
23. Rajendran R, Ganesan N, Balu SK, Alagar S, Thandavamoorthy 
P, Thiruvengadam D. Green synthesis, characterization, 
antimicrobial and cytotoxic effects of silver nanoparticles using 
origanum heracleoticum L. leaf extract. Int J Pharm Pharm Sci 
2015;7:288-93. 
24. Selvarani M. Investigation of the synergistic antibacterial action 
of copper nanoparticles on certain antibiotics against human 
pathogens. Int J Pharm Pharm Sci 2018;10:83-6. 
25. Panahi Y, Farshbaf M, Mohammadhosseini M. Recent advances 
on liposomal nanoparticles: synthesis, characterization and 
biomedical applications [published correction appears in artif 
cells nanomed biotechnol 2019 Dec; 47:2306]. Artif Cells 
Nanomed Biotechnol 2017;45:788-99. 
26. Bonde S, Nair S. Advances in liposomal drug delivery system: 
fascinating types and potential applications. Int J Appl Pharm 
2017;9:1-7. 
27. Ghafelehbashi R, Akbarzadeh I, Tavakkoli Yaraki M, Lajevardi 
A, Fatemizadeh M, Heidarpoor Saremi L. Preparation, 
physicochemical properties, in vitro evaluation and release 
behavior of cephalexin-loaded niosomes. Int J Pharm 
2019;569:118580. 
28. Thaya R, Vaseeharan B, Sivakamavalli J, Iswarya A, 
Govindarajan M, Alharbi NS, et al. Synthesis of chitosan-
alginate microspheres with high antimicrobial and antibiofilm 
activity against multi-drug resistant microbial pathogens. 
Microb Pathog 2018;114:17-24. 
29. Adebisi AO, Conway BR. Lectin-conjugated microspheres for 
eradication of Helicobacter pylori infection and interaction with 
mucus. Int J Pharm 2014;470:28-40. 
30. Xu W, Dong S, Han Y, Li S, Liu Y. Hydrogels as antibacterial 
biomaterials. Curr Pharm Des 2018;24:843-54. 
31. Kesharwani, Prashant, Jain, Keerti, Jain, Narendra. Dendrimer as 
nanocarrier for drug delivery. Prog Polym Sci 2014;39:268–307.  
32. Li C, Zhou K, Chen D. Solid lipid nanoparticles with enteric 
coating for improving stability, palatability, and oral 
bioavailability of enrofloxacin. Int J Nanomed 2019;14:1619-31. 
33. Jansook P, Pichayakorn W, Ritthidej GC. Amphotericin B-loaded 
solid lipid nanoparticles (SLNs) and nanostructured lipid 
carrier (NLCs): effect of drug loading and biopharmaceutical 
characterizations. Drug Dev Ind Pharm 2018;44:1693-700.  
34. Chokshi NV, Khatri HN, Patel MM. Formulation, optimization, 
and characterization of rifampicin-loaded solid lipid 
nanoparticles for the treatment of tuberculosis. Drug Dev Ind 
Pharm 2018;44:1975-89. 
35. Zhou W, Jia Z, Xiong P. Novel pH-responsive tobramycin-
embedded micelles in nanostructured multilayer-coatings of 
chitosan/heparin with efficient and sustained antibacterial 
properties. Mater Sci Eng C Mater Biol Appl 2018;90:693-705.  
36. Harwansh RK, Deshmukh R, Rahman MA. Nanoemulsion: 
promising nanocarrier system for delivery of herbal bioactives. 
J Drug Delivery Sci Technol 2019;51:224-33. 
37. Wallace SJ, Nation RL, Li J, Boyd BJ. Physicochemical aspects of 
the coformulation of colistin and azithromycin using liposomes 
for combination antibiotic therapies. J Pharm Sci 
2013;102:1578–87. 
38. Alhariri M, Majrashi MA, Bahkali AH. Efficacy of neutral and 
negatively charged liposome-loaded gentamicin on planktonic 
bacteria and biofilm communities. Int J Nanomed 
2017;12:6949-61. 
39. Rotov KA, Tikhonov SN, Alekseev VV, Snatenkov EA. 
Pharmacokinetics of liposomal gentamicin. Bull Exp Biol Med 
2012;153:475–7. 
40. Fattal E, Rojas J, Roblot Treupel L, Andremont A, Couvreur P. 
Ampicillin-loaded liposomes and nanoparticles: comparison of 
drug loading, drug release and in vitro antimicrobial activity. J 
Microencapsulation 1991;8:29–36. 
41. Fattal E, Rojas J, Youssef M, Couvreur P, Andremont A. 
Liposome-entrapped ampicillin in the treatment of 
experimental murine listeriosis and salmonellosis. Antimicrob 
Agents Chemother 1991;35:770–2. 
42. Antonela Antoniu S. Inhaled ciprofloxacin for chronic airways 
infections caused by Pseudomonas aeruginosa. Expert Rev Anti 
Infect Ther 2012;10:1439–46. 
43. Kadry AA, Al-Suwayeh SA, Abd-Allah ARA, Bayomi MA. 
Treatment of experimental osteomyelitis by liposomal 
antibiotics. J Antimicrob Chemother 2004;54:1103–8. 
44. Liu C, Shi J, Dai Q, Yin X, Zhang X, Zheng A. In vitro and in vivo 
evaluation of ciprofloxacin liposomes for pulmonary 
administration. Drug Dev Ind Pharm 2015;41:272-8.  
45. Wong JP, Yang H, Blasetti KL, Schnell G, Conley J, Schofield LN. 
Liposome delivery of ciprofloxacin against intracellular Francisella 
tularensis infection. J Controlled Release 2003;92:265–73. 
46. Radovic Moreno AF, Lu TK, Puscasu VA, Yoon CJ, Langer R, 
Farokhzad OC. Surface charge-switching polymeric 
nanoparticles for bacterial cell wall-targeted delivery of 
antibiotics. ACS Nano 2012;6:4279–87. 
47. Brown AN, Smith K, Samuels TA, Lu J, Obare SO, Scott ME. 
Nanoparticles functionalized with ampicillin destroy multiple-
antibiotic-resistant isolates of Pseudomonas aeruginosa and 
Enterobacter aerogenes and methicillin-resistant Staphylococcus 
aureus. Appl Environ Microbiol 2012;78:2768–74. 
48. He J, Abdelraouf K, Ledesma KR, Chow DS, Tam VH. 
Pharmacokinetics and efficacy of liposomal polymyxin B in a 
murine pneumonia model. Int J Antimicrob Agents 
2013;42:559–64. 
49. Azhdarzadeh M, Lotfipour F, Zakeri Milani P, Mohammadi G, 
Valizadeh H. Anti-bacterial performance of azithromycin 
nanoparticles as colloidal drug delivery system against different 
gram-negative and gram-positive bacteria. Adv Pharm Bull 
2012;2:17–24. 
50. Mohammadi G, Valizadeh H, Barzegar Jalali M, Lotfipour F, 
Adibkia K, Milani M, et al. Development of azithromycin–PLGA 
nanoparticles: physicochemical characterization and 
antibacterial effect against Salmonella typhi. Colloids Surf Bio 
Interfaces 2010;80:34–9. 
51. Gajendiran M, Gopi V, Elangovan V, Murali RV, 
Balasubramanian S. Isoniazid loaded core-shell nanoparticles 
derived from PLGA-PEG-PLGA tri-blockcopolymers: in vitro and 
in vivo drug release. Colloids Surf B 2013;104:107–15. 
52. Kalluru R, Fenaroli F, Westmoreland D, Ulanova L, Maleki A, 
Roos N, et al. Poly(lactide-co-glycolide)–rifampicin 
nanoparticles efficiently clear Mycobacterium bovis BCG 
infection in macrophages and remain membrane-bound in 
phago-lysosomes. J Cell Sci 2013;126:3043–54. 
53. Ghaffari S, Varshosaz J, Saadat A, Atyabi F. Stability and 
antimicrobial effect of amikacin-loaded solid lipid 
nanoparticles. Int J Nanomed 2011;6:35–43. 
54. Abul Kalam M, Sultana Y, Ali A, Aqil M, Mishra AK, Chuttani K, et 
al. Part II: enhancement of transcorneal delivery of gatifloxacin 
by solid lipid nanoparticles in comparison to commercial 
aqueous eye drops. J Biomed Mater Res A 2013;101:1828–36. 
55. Wang Y, Zhu L, Dong Z, Xie S, Chen X, Lu M, et al. Preparation and 
stability study of norfloxacin-loaded solid lipid nanoparticle 
suspensions. Colloids Surf Bio Interfaces 2012;98:105–11. 
56. Kumar PV, Asthana A, Dutta T, Jain NK. Intracellular 
macrophage uptake of rifampicin loaded mannosylated 
dendrimers. J Drug Target 2006;14:546–56. 
Deshmukh et al. 
Int J App Pharm, Vol 13, Issue 1, 2021, 36-42 
42 
57. Choi SK, Myc A, Silpe JE, Sumit M, Wong PT, McCarthy K, et al. 
Dendrimer-based multivalent vancomycin nano platform for 
targeting the drug-resistant bacterial surface. ACS Nano 
2013;7:214–28. 
58. Navath RS, Menjoge AR, Dai H, Romero R, Kannan S, Kannan 
RM. Injectable PAMAM dendrimer–PEG hydrogels for the 
treatment of genital infections: formulation and in vitro and in 
vivo evaluation. Mol Pharm 2011;8:1209–23. 
59. Kumar P, Narang RK, Swamy S. Development and evaluation of 
nanoparticle-loaded hydrogel of co-trimoxazole. Int J Pharm Sci 
Nanotechnol 2016;9:3131-41. 
60. Attama AA, Onuigbo EB. Properties of co-trimoxazole 
microparticles prepared with carbopol 941 and exogenous 
mucin. Sci Res Essays 2007;2:421-5. 
61. Amaral AC, Marques AF, Munoz JE. Poly (lactic acid-glycolic 
acid) nanoparticles markedly improve immunological 
protection provided by peptide P10 against murine 
paracoccidioidomycosis. Br J Pharmacol 2010;159:1126-32. 
62. Bottari NB, Baldissera MD, Tonin AA, Rech VC, Alves CB, DAvila F, et 
al. Synergistic effects of resveratrol (free and inclusion complex) 
and sulfamethoxazole-trimetropim treatment on pathology, 
oxidant/antioxidant status and behavior of mice infected with 
Toxoplasma gondii. Microb Pathog 2016;95:166-74. 
63. Mendes C, Valentini G, Chamorro Rengifo AF, Pinto JMO, Silva 
MAS, Parize AL. Supersaturating drug delivery system of fixed 
drug combination: sulfamethoxazole and trimethoprim. Expert 
Rev Anti Infect Ther 2019;17:841-50. 
64. Gurbuz MU, Erturk AS, Tulu M. Synthesis of surface-modified 
TREN-cored PAMAM dendrimers and their effects on the 
solubility of sulfamethoxazole (SMZ) as an analog antibiotic 
drug. Pharm Dev Technol 2017;22:678-89.  
65. Gokturk S, Çalışkan E, Talman RY, Var U. A study on 
solubilization of poorly soluble drugs by cyclodextrins and 
micelles: complexation and binding characteristics of 
sulfamethoxazole and trimethoprim. Sci World J 
2012;2012:718791. 
66. Bodaghabadi N, Hajigholami S, Malekshahi ZV, Entezari M, 
Najafi F, Shirzad H, et al. Preparation and evaluation of 
rifampicin and co-trimoxazole-loaded nanocarrier against 
Brucellamelitensis infection. Iranian Biomed J 2018;22:275-82. 
 
